Scarica l'app Stockscreener
177.34
3.50%
-6.44
Dopo l'orario di chiusura:
177.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$183.78
Aprire:
$181.46
Volume 24 ore:
1.34M
Relative Volume:
1.03
Capitalizzazione di mercato:
$26.03B
Reddito:
$9.53B
Utile/perdita netta:
$1.29B
Rapporto P/E:
20.14
EPS:
8.8057
Flusso di cassa netto:
$1.97B
1 W Prestazione:
-7.18%
1M Prestazione:
-5.70%
6M Prestazione:
+14.23%
1 anno Prestazione:
+35.04%
Intervallo 1D:
$176.39
$181.98
Intervallo di 1 settimana:
$171.37
$191.06
Portata 52W:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
177.34 | 26.03B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen Inc. (BIIB) stock price, news, quote and history - Yahoo Finance Singapore
BIIB (Biogen) 3-Year Revenue Growth Rate : -1.20% (As of Dec. 2025) - GuruFocus
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance Singapore
Stifel Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $214 - Moomoo
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC - MarketBeat
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Biogen (BIIB) CAO Sean Godbout nets shares from RSU vesting and tax withholding - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Biogen Inc stock: Plunges to $177.34 – What it means for you - AD HOC NEWS
Rx Rundown: Eli Lilly, Blackstone, Biogen and more - Medical Marketing and Media
Nisa Investment Advisors LLC Sells 9,121 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS - RTTNews
Biogen Inc. (BIIB) Stock Forecasts - finance.yahoo.com
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - finance.yahoo.com
Biogen (NASDAQ:BIIB) Target Revision Sparks Nasdaq Futures Focus - Kalkine Media
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
H.C. Wainwright raises Biogen stock price target on Apellis deal By Investing.com - Investing.com India
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
BIIB Analyst Rating: HC Wainwright & Co. Raises Price Target to $237 | BIIB Stock News - GuruFocus
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - IndexBox
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
Canaccord Genuity Raises Price Target for Biogen (BIIB) to $245 - GuruFocus
Mass. companies close major deals in biotech, media in March - The Business Journals
Biogen Inc (BSP:BIIB34) Stock Price, Trades & News - gurufocus.com
Oppenheimer Raises Biogen (BIIB) Price Target to $275, Maintains Outperform Rating | BIIB Stock News - GuruFocus
FDA Approves Higher-Dose Regimen of Nusinersen for Spinal Muscular Atrophy - Pharmacy Times
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion - Investing.com
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com India
Biogen stock is locked into a rising trendline — And $202.41 is the destination - fxstreet.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - Pharmaceutical Executive
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - finance.yahoo.com
Biogen (NASDAQ:BIIB) Price Target Raised to $191.00 - MarketBeat
Biogen (NASDAQ:BIIB) Given New $275.00 Price Target at Oppenheimer - MarketBeat
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - biospace.com
Biogen (NASDAQ:BIIB) Price Target Raised to $245.00 at Canaccord Genuity Group - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Canaccord Genuity Adjusts Biogen PT to $245 From $230, Maintains Buy Rating - MarketScreener
Oppenheimer Adjusts Price Target on Biogen to $275 From $250, Maintains Outperform Rating - MarketScreener
Biogen stock price target raised to $245 by Canaccord on Apellis deal - Investing.com
Wedbush Raises Price Target on Biogen to $191 From $187, Keeps Neutral Rating - marketscreener.com
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - finance.yahoo.com
Apellis Pharmaceuticals to be Acquired by Biogen in Merger - TipRanks
Biogen bolsters immunology offerings with $5.6bn Apellis buy - bioxconomy.com
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger - finance.yahoo.com
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio - TipRanks
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):